share_log

卫信康(603676.SH):子公司获得药物临床试验批准通知书

Tibet Weixinkang Pharmaceutical (603676.SH): Subsidiary receives drug clinical trial approval notice.

Gelonghui Finance ·  Sep 6 03:42

Gelonghui, September 6 | Wei Xinkang (603676.SH) announced that Beijing Tibetan Weixinkang Pharmaceutical Research & Development Co., Ltd. (“Zangwei Xinkang”), a wholly-owned subsidiary of the company, has received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The deoxycholic acid injection declared by the company's wholly-owned subsidiary Zangwei Xinkang was developed using Belkyra listed on Allergan Pharmaceuticals International/ABBVIE S.r.l., as a reference formulation. The indication is that it can be used to improve moderate to severe profile bulges or excessive facial fullness caused by fat accumulation under the chin in adults. The original research product is currently not marketed in China.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment